FDA calendar
Upcoming FDA decision dates, advisory committee meetings and EU opinions, alongside recent FDA decisions and announcements. Updated automatically every day from the FDA newsroom, openFDA, the Federal Register and company announcements.
Coming up
November 2026
- 22SunPDUFA dateCapricor Therapeutics Β· DeramiocelDuchenne muscular dystrophy Β· Cell therapy BLA; date extended after major amendmentCapricor (SEC filing) β
- 27FriPDUFA dateBridgeBio Pharma Β· BBP-418Limb-girdle muscular dystrophy type 2I/R9 Β· Priority reviewPR Newswire β
- 30Mon
- 30MonPDUFA dateVertex Pharmaceuticals Β· PovetaciceptIgA nephropathy Β· Accelerated approval, priority reviewPR Newswire β
December 2026
- 3Thu
- 12SatPDUFA dateVanda Pharmaceuticals Β· QuimilzaGeneralised pustular psoriasis Β· BLAVanda (SEC filing) β
- 27SunPDUFA datePraxis Precision Medicines Β· RelutrigineSCN2A and SCN8A developmental and epileptic encephalopathiesPraxis β
- 27SunPDUFA dateViatris Β· MR-107A-02 (fast-acting meloxicam)Moderate-to-severe acute pain Β· Non-opioidPR Newswire β
- 30WedPDUFA dateCogent Biosciences Β· BezuclastinibNon-advanced systemic mastocytosisCogent (SEC filing) β
January 2027
- 21ThuPDUFA dateDyne Therapeutics Β· Zeleciment rostudirsen (DYNE-251)Duchenne muscular dystrophy, exon 51 Β· Accelerated approval, priority reviewNeurologyLive β
- 29Fri
- 30SatPDUFA datePharming Β· Joenja (leniolisib)APDS in younger children Β· Paediatric label expansion, priority reviewRallies β
June 2027
- 29Tue
Recent FDA decisions and announcements
November 2026
- 9Mon
- 9MonFDA approvalFDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High RiskFDA press release β
- 5ThuFDA approvalFDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaFDA press release β
- 2MonFDA announcementFDA Provides Clarity to Support Cell and Gene Therapy Development and QualityFDA press release β
October 2026
- 30FriFDA approvalFDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory PapillomatosisFDA press release β
- 30Fri
- 30FriFDA approvalFDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory PapillomatosisFDA press release β
- 27Tue
- 22Thu
- 22Thu
- 22Thu
- 22ThuFDA announcementFDA Launches New Program to Advance Neuroscience Medical Product DevelopmentFDA press release β
- 20TueFDA approvalGlaxosmithkline LLC Β· Hibsago (bepirovirsen)New molecular entity, priority reviewDrugs@FDA β
- 20Tue
- 20Tue
- 20TueFDA announcementFDA Issues Final Guidance on Prescription Drug Apps and SoftwareFDA press release β
- 19MonFDA approvalFDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and SurgeryFDA press release β
- 19MonFDA approvalFDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and SurgeryFDA press release β
- 14WedFDA announcementFDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug DevelopmentFDA press release β
- 14WedFDA approvalFDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder CancerFDA press release β
- 14WedFDA announcementFDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug DevelopmentFDA press release β
- 9FriFDA approvalAicuris Anti-Infect Β· Hovilpri (pritelivir mesylate)New molecular entity, priority reviewDrugs@FDA β
- 5Mon
- 1Thu
September 2026
- 30WedFDA announcementFDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory CommitteesFDA press release β
- 29TueFDA announcementFDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution SchemeFDA press release β
- 28Mon
- 28Mon
- 25FriFDA approvalMirum Β· Atebrioz (zilurgisertib fumarate)New molecular entity, priority reviewDrugs@FDA β
- 23WedFDA announcementFederal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse ConditionsFDA press release β
- 23WedFDA approvalElevar Β· Lyrfigtu (lirafugratinib hydrochloride)New molecular entity, priority reviewDrugs@FDA β
- 17ThuFDA approvalFDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type AFDA press release β
- 16Wed
August 2026
- 26WedFDA approvalRevolution Medicines Β· Rasonque (daraxonrasib)New molecular entity, priority reviewDrugs@FDA β
- 13ThuFDA approvalBristol Myers Squibb Β· Zenbexus (iberdomide hydrochloride)New molecular entity, priority reviewDrugs@FDA β
- 13Thu
- 5WedFDA approvalTakeda Pharms USA Β· Orzeyful (oveporexton)New molecular entity, priority reviewDrugs@FDA β
July 2026
- 31Fri
- 30Thu
- 29Wed
- 24FriFDA approvalOutlook Therapeutics, Inc. Β· Lytenava (bevacizumab-vikg)New biologic licenceDrugs@FDA β
